The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 562.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 8.00 (1.429%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 562.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Trading Update

21 Feb 2024 07:00

RNS Number : 8339D
Gooch & Housego PLC
21 February 2024
 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation (EU no. 596/2014) as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 (as amended from time to time).

 

 

21 February 2024

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

AGM Trading Update

 

"Further order book growth but near-term demand impacted by destocking"

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, will hold its Annual General Meeting at 11.00 a.m. today at the Company's headquarters in Ilminster, Somerset.

 

In the first four months of the financial year the Group's order book has increased to £128.5m (September 2023: £124.1m) supported by strong intake from our medical diagnostic customers and new orders for our armoured vehicle periscope systems. We have also secured an important new customer in the sub-sea data communications market which will ramp-up to support revenues in the second half of FY2024.

 

The Group has made further progress in implementing operational improvements in its production facilities and has continued to reduce lead times offered to customers. We are delivering on our strategy of transferring additional product lines to our lower cost contract manufacturing partners which will support greater operational capacity and flexibility as well as some medium-term margin expansion.

 

As previously stated, some of our customers in the Industrial and Medical laser markets have been reducing their inventory holdings and reporting near term demand weakness from some end markets. This period of inventory adjustment is proving to be deeper and more prolonged than previously anticipated. Our semiconductor market customers have reduced near-term demand but still expect strong growth in the medium term. We have also received customer notification that certain US A&D programmes will no longer go ahead or have been deferred.

 

As a result, the Group's trading for FY2024 is expected to be more weighted to the second half and profit growth for the full year to be lower. Adjusted profit before tax is anticipated to be circa £3 million below management's previous expectations.

 

Given the strong medium term customer demand demonstrated by a growing order book, recent operational improvements and the Group's strategic focus, we believe we remain extremely well placed to respond quickly and benefit as several key end markets recover.

 

Strategy Update

 

The Group is executing against the recently communicated strategic objectives and is making strong progress. The build out of the production and R&D facilities at our new US medical diagnostics hub located within the GS Optics campus in Rochester, NY is progressing well. We have secured our first customer order for our US R&D team at the facility and are in discussions with a number of other Life Sciences customers for further R&D and production orders to be supplied from the facility. Our review of the Group's product portfolio is well advanced and near-term actions in this area are expected to support the future profit margin improvement of the Group, especially in our A&D business.

 

The integration of the recently acquired GS Optics and Artemis businesses within the Group is well advanced. The commercial synergies anticipated from the combination of our precision optics capabilities with Artemis' thin film coating services has been confirmed by some recent new contract awards and further large orders are being pursued. Whilst in the near-term GS Optics is impacted by the slowdown in demand from destocking by some of its Industrial market customers, we have received significant levels of interest from the Group's customers in our new polymer optics capabilities.

 

The Group's financial position remains strong. Working capital levels have been reduced in the first four months of the financial year and net debt at the end of January 2024 stood at £30.5m (Sept 2023: £31.7m).

 

Charlie Peppiatt, Chief Executive Officer of Gooch and Housego, commented:

"Whilst we are pleased with the order book growth, reduction in lead times and strategic progress, the Group's performance is likely to be impacted in the near term by market dynamics. Nonetheless, we remain focused on executing on our strategic objectives and our improved customer service has been recognised with important new orders from both existing and new customers.

"Our review of the Group's product portfolio is nearing completion. This will be an important contributor in improving the profitability of the Group, especially in our A&D business.

"G&H is well positioned in structural growth markets and is executing on its strategic plan that will deliver sustainable margin growth for the Group."

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / Sophie Wills / Abigail Gilchrist

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Jewell, Chief Financial Officer.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUQUPUPCGBU
Date   Source Headline
20th Feb 20191:07 pmRNSResult of AGM
20th Feb 20197:00 amRNSAGM Trading Update
9th Jan 201910:17 amRNSGrant of LTIP Awards
9th Jan 20197:00 amRNSSite Visit to ITL Life Science Business
28th Dec 201811:14 amRNSBlock Listing Six Monthly Return
28th Dec 201811:13 amRNSIssue of Equity and Total Voting Rights
28th Dec 201811:12 amRNSBlock Listing Application
11th Dec 20184:44 pmRNSAdditional Listing
11th Dec 20187:00 amRNSPosting of Annual Report and AGM Notice
5th Dec 201811:30 amRNSDirector/PDMR Shareholding
5th Dec 201811:28 amRNSDirector/PDMR Shareholding
27th Nov 201811:36 amRNSDirector/PDMR Shareholding
27th Nov 20187:00 amRNSCFO Succession
27th Nov 20187:00 amRNSPreliminary Results
30th Oct 201811:06 amRNSHolding(s) in Company
29th Oct 201811:08 amRNSHolding(s) in Company
25th Oct 20184:40 pmRNSHolding(s) in Company
25th Oct 20187:00 amRNSNotification of Preliminary Results
23rd Oct 201810:23 amRNSHolding(s) in Company
4th Oct 20187:00 amRNSFull Year Trading Update
26th Sep 20189:00 amRNSHolding(s) in Company
6th Sep 20187:00 amRNSAerospace and Defence Acquisition
8th Aug 20187:00 amRNSLife Sciences Acquisition
12th Jul 20189:26 amRNSHolding(s) in Company
13th Jun 201810:08 amRNSHolding(s) in Company
6th Jun 20182:02 pmRNSDirector/PDMR Shareholding
5th Jun 20187:00 amRNSInterim Results
3rd May 20187:00 amRNSNotification of Half Year Results
6th Apr 20187:00 amRNSHalf Year Trading Update
3rd Apr 20184:35 pmRNSPrice Monitoring Extension
20th Mar 20188:25 amRNSHolding(s) in Company
21st Feb 20185:20 pmRNSResult of AGM
21st Feb 20187:00 amRNSAGM Trading Update
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
22nd Jan 20181:00 pmRNSDirector/PDMR shareholding
18th Jan 20181:35 pmRNSGrant of LTIP Awards
22nd Dec 20179:13 amRNSBlock Listing Application
22nd Dec 20177:00 amRNSAppointment of Non-Executive Chairman
15th Dec 20177:00 amRNSPosting of Annual Report and AGM Notice
28th Nov 20177:00 amRNSPreliminary Results
23rd Oct 20177:00 amRNSNotification of Full Year Results
4th Oct 20177:00 amRNSFull Year Trading Update
3rd Oct 20174:36 pmRNSHolding(s) in Company
3rd Oct 20174:31 pmRNSHolding(s) in Company
25th Aug 20174:33 pmRNSHolding(s) in Company
16th Aug 20173:54 pmRNSHolding(s) in Company
6th Jun 20177:00 amRNSInterim Results
16th May 20176:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.